ScripMerck & Co. could have an edge in the cholesterol market with the first oral PCSK9 inhibitor. The company announced positive topline data on June 9 from the first two Phase III trials testing enli
ScripThe US Food and Drug Administration approved Merck & Co.’s Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infa
ScripIn the week that Merck & Co.’s competing respiratory syncytial virus (RSV) antibody, clesrovimab, could get US approval , Sanofi and partner AstraZeneca are bringing forward the shipping of their
ScripIf Merck & Co is indeed poised to raise its buyout offer for MoonLake Therapeutics, a takeover could give it an entry into a multi-billion dollar inflammation and immunology franchise. The big pha